GSG2 facilitates the progression of human breast cancer through MDM2-mediated ubiquitination of E2F1

[1]  K. Hess,et al.  Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Qiang Wang,et al.  Effects and mechanisms of GSG2 in esophageal cancer progression , 2022, Journal of Cancer Research and Clinical Oncology.

[3]  L. Connelly,et al.  Targeted therapy for breast cancer: An overview of drug classes and outcomes. , 2022, Biochemical pharmacology.

[4]  X. Dang,et al.  GSG2 promotes tumor growth through regulating cell proliferation in hepatocellular carcinoma. , 2021, Biochemical and biophysical research communications.

[5]  K. Tokuhiro,et al.  Evaluation of the antiproliferative effects of the HASPIN inhibitor CHR-6494 in breast cancer cell lines , 2021, PloS one.

[6]  Wei Zhang,et al.  Targeting the Ubiquitin Signaling Cascade in Tumor Microenvironment for Cancer Therapy , 2021, International journal of molecular sciences.

[7]  R. Lu,et al.  GSG2 Promotes Development and Predicts Poor Prognosis of Ovarian Cancer , 2021, Cancer management and research.

[8]  A. Jemal,et al.  Cancer Statistics, 2021 , 2021, CA: a cancer journal for clinicians.

[9]  Chunhong Hu,et al.  Novel Potential Therapeutic Target for E2F1 and Prognostic Factors of E2F1/2/3/5/7/8 in Human Gastric Cancer , 2020, Molecular therapy. Methods & clinical development.

[10]  Feng Xu,et al.  GSG2 (Haspin) promotes development and progression of bladder cancer through targeting KIF15 (Kinase-12) , 2020, Aging.

[11]  Jacob D. Jaffe,et al.  Synthetic Lethal and Resistance Interactions with BET Bromodomain Inhibitors in Triple-Negative Breast Cancer. , 2020, Molecular cell.

[12]  J. Dai,et al.  Haspin inhibition delays cell cycle progression through interphase in cancer cells , 2020, Journal of cellular physiology.

[13]  L. Farahmand,et al.  Breast cancer: Biology, biomarkers, and treatments. , 2020, International immunopharmacology.

[14]  S. Lens,et al.  Untangling the contribution of Haspin and Bub1 to Aurora B function during mitosis , 2020, The Journal of cell biology.

[15]  X. Gu,et al.  HASPIN is involved in the progression of gallbladder carcinoma. , 2020, Experimental cell research.

[16]  D. Schadendorf,et al.  Inhibition of Haspin kinase promotes cell-intrinsic and extrinsic anti-tumor activity. , 2019, Cancer research.

[17]  Wei Yue,et al.  Semi-quantitative Determination of Protein Expression using Immunohistochemistry Staining and Analysis: An Integrated Protocol. , 2019, Bio-protocol.

[18]  Xu Han,et al.  Haspin knockdown can inhibit progression and development of pancreatic cancer in vitro and vivo. , 2019, Experimental cell research.

[19]  Hui Zhang,et al.  Resveratrol Inhibits the Migration and Metastasis of MDA-MB-231 Human Breast Cancer by Reversing TGF-β1-Induced Epithelial-Mesenchymal Transition , 2019, Molecules.

[20]  G. Grassi,et al.  E2F1 as a molecular drug target in ovarian cancer , 2019, Expert opinion on therapeutic targets.

[21]  Xin Liu,et al.  Bioinformatic Analysis Reveals GSG2 as a Potential Target for Breast Cancer Therapy , 2019, Open life sciences.

[22]  J. Shih,et al.  Epithelial-mesenchymal transition (EMT) beyond EGFR mutations per se is a common mechanism for acquired resistance to EGFR TKI , 2018, Oncogene.

[23]  V. Mittal.  Epithelial Mesenchymal Transition in Tumor Metastasis. , 2018, Annual review of pathology.

[24]  Jianfei Qi,et al.  Ubiquitin ligases in oncogenic transformation and cancer therapy , 2017, Nature Reviews Cancer.

[25]  C. Roussakis,et al.  Haspin: a promising target for the design of inhibitors as potent anticancer drugs. , 2017, Drug discovery today.

[26]  Stephen P. Jackson,et al.  Deubiquitylating enzymes and drug discovery: emerging opportunities , 2017, Nature Reviews Drug Discovery.

[27]  A. Guerrero-Zotano,et al.  PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment , 2016, Cancer and Metastasis Reviews.

[28]  R. Chen,et al.  E2F1 and NF-κB: Key Mediators of Inflammation-associated Cancers and Potential Therapeutic Targets. , 2016, Current cancer drug targets.

[29]  Wenliang Li,et al.  Epithelial-mesenchymal transition in human cancer: comprehensive reprogramming of metabolism, epigenetics, and differentiation. , 2015, Pharmacology & therapeutics.

[30]  H. Jia,et al.  p53 Suppresses E2F1-dependent PLK1 expression upon DNA damage by forming p53-E2F1-DNA complex. , 2013, Experimental cell research.

[31]  B. Zhou,et al.  The Role of Snail in EMT and Tumorigenesis. , 2013, Current cancer drug targets.

[32]  X. Chen,et al.  Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. , 2011, The Journal of clinical investigation.

[33]  Susan S. Taylor,et al.  Protein kinases: evolution of dynamic regulatory proteins. , 2011, Trends in biochemical sciences.

[34]  M. Ares,et al.  Purification of RNA using TRIzol (TRI reagent). , 2010, Cold Spring Harbor protocols.

[35]  M. Tortorici,et al.  Crystal structure of the catalytic domain of Haspin, an atypical kinase implicated in chromatin organization , 2009, Proceedings of the National Academy of Sciences.

[36]  Daniela Hoeller,et al.  Targeting the ubiquitin system in cancer therapy , 2009, Nature.

[37]  K. Hess,et al.  Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  B. Pützer.  E2F1 death pathways as targets for cancer therapy , 2007, Journal of cellular and molecular medicine.

[39]  B. Yung,et al.  Nucleophosmin/B23 regulates transcriptional activation of E2F1 via modulating the promoter binding of NF-kappaB, E2F1 and pRB. , 2006, Cellular signalling.

[40]  B. Sullivan,et al.  Regulation of mitotic chromosome cohesion by Haspin and Aurora B. , 2006, Developmental cell.

[41]  Sudhir Agrawal,et al.  Stabilization of E2F1 protein by MDM2 through the E2F1 ubiquitination pathway , 2005, Oncogene.

[42]  S. Cox,et al.  A cyclin D1/cyclin-dependent kinase 4 binding site within the C domain of the retinoblastoma protein. , 2001, Cancer research.

[43]  H. Nojima,et al.  Isolation and characterization of cDNA clones specifically expressed in testicular germ cells , 1994, FEBS letters.

[44]  Rania M Khalil.  Ubiquitin-Proteasome Pathway and Muscle Atrophy. , 2018, Advances in experimental medicine and biology.

[45]  Brigitte M Pützer,et al.  The E2F1-miRNA cancer progression network. , 2013, Advances in experimental medicine and biology.

[46]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..